A diagnostics company has reached a settlement with a consumer watchdog organization, agreeing to halt the sale of two questionable blood tests following accusations of false and misleading advertising. EpicGenetics, led by founder and CEO Bruce Gillis, has been under scrutiny for its claims surrounding the efficacy of these tests.
The Center for Science in the Public Interest filed a lawsuit in October 2023, alleging that EpicGenetics had been promoting one of its blood tests as a definitive diagnostic tool for fibromyalgia, a chronic pain condition. Additionally, the company was accused of fabricating a disease in order to justify the use of another product and falsely offering nonexistent treatment trials to lure in patients.
While EpicGenetics and its affiliates continue to maintain their innocence, they have agreed to cease the marketing and sale of these two tests as part of the settlement. The terms also include restrictions on the claims that can be made about other products and a payment of $158,000 to cover the legal fees of the Center for Science in the Public Interest. The settlement officially took effect on July 30.
It is important to note that access to the full details of this article is exclusive to STAT+ subscribers. By subscribing, individuals can unlock this article along with in-depth analysis, newsletters, premium events, and networking platform access. Subscribers gain unlimited access to award-winning journalism and exclusive events, providing a comprehensive understanding of the latest developments in the healthcare industry.
For more information on subscription plans and to access this exclusive content, interested readers can visit the STAT+ website. Stay informed and stay connected with the latest updates and insights from the world of diagnostics and healthcare.
